Literature DB >> 15755793

Discovery, clinical development, and therapeutic uses of bisphosphonates.

Angelo A Licata1.   

Abstract

OBJECTIVE: To review the literature concerning the history, development, and therapeutic uses of bisphosphonates. DATA SOURCES: English-language articles were identified through a search of MEDLINE (through December 2004) using the key word bisphosphonate. Reference lists of pivotal studies, reviews, and full prescribing information for the approved agents were also examined. STUDY SELECTION AND DATA EXTRACTION: Selected studies included those that discussed the discovery and initial applications of bisphosphonates, as well as their historical development, pharmacokinetic and pharmacodynamic properties, and current therapeutic uses. DATA SYNTHESIS: Bisphosphonates structurally resemble pyrophosphates (naturally occurring polyphosphates) and have demonstrated similar physicochemical effects to pyrophosphates. In addition, bisphosphonates reduce bone turnover and resist hydrolysis when administered orally. The information gained from initial work with etidronate generated a considerable scientific effort to design new and more effective bisphosphonates. The PCP moiety in the general bisphosphonate structure is essential for binding to hydroxyapatite and allows for a number of chemical variations by changing the 2 lateral side chains (designated R(1) and R(2)). The R(1) side chain determines binding affinity to hydroxyapatite, and the R(2) side chain determines antiresorptive potency. Accordingly, each bisphosphonate has its own characteristic profile of activity.
CONCLUSIONS: The bisphosphonates reduce bone turnover, increase bone mass, and decrease fracture risk and therefore have a significant place in the management of skeletal disorders including osteoporosis, Paget's disease, bone metastases, osteogenesis imperfecta, and heterotopic ossification.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755793     DOI: 10.1345/aph.1E357

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  48 in total

Review 1.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

2.  Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice.

Authors:  Yasuyoshi Kobayashi; Toru Hiraga; Akimi Ueda; Liyang Wang; Michiyo Matsumoto-Nakano; Kenji Hata; Hirofumi Yatani; Toshiyuki Yoneda
Journal:  J Bone Miner Metab       Date:  2009-10-31       Impact factor: 2.626

3.  Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management.

Authors:  Joseph L Shaker
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

4.  Trinuclear Metal Clusters in Catalysis by Terpenoid Synthases.

Authors:  Julie A Aaron; David W Christianson
Journal:  Pure Appl Chem       Date:  2010       Impact factor: 2.453

5.  Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration.

Authors:  Amel Dudakovic; Huaxiang Tong; Raymond J Hohl
Journal:  Invest New Drugs       Date:  2010-05-18       Impact factor: 3.850

6.  Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw.

Authors:  Parish P Sedghizadeh; Allan C Jones; Chris LaVallee; Roger W Jelliffe; Anh D Le; Peter Lee; Andrew Kiss; Michael Neely
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-12-12

7.  Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts.

Authors:  Je-Tae Woo; Makoto Kawatani; Masanori Kato; Toshimasa Shinki; Takayuki Yonezawa; Naoki Kanoh; Hiroshi Nakagawa; Masamichi Takami; Kun Hyung Lee; Paula H Stern; Kazuo Nagai; Hiroyuki Osada
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

Review 8.  Pharmacologic augmentation of implant fixation in osteopenic bone.

Authors:  R D Ross; J L Hamilton; B M Wilson; D R Sumner; A S Virdi
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

9.  Metagenomic investigation of microbes and viruses in patients with jaw osteonecrosis associated with bisphosphonate therapy.

Authors:  Parish P Sedghizadeh; Shibu Yooseph; Douglas W Fadrosh; Lisa Zeigler-Allen; Mathangi Thiagarajan; Hamid Salek; Farid Farahnik; Shannon J Williamson
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-12

Review 10.  Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature.

Authors:  Jan Rustemeyer; Andreas Bremerich
Journal:  Clin Oral Investig       Date:  2009-06-04       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.